[LG Chem Press Release] LG Chem has granted global licensing rights for an oral treatment for rare obesity disorders to U.S.-based Rhythm Pharmaceuticals, which is now set to begin its active development.

On the July 24th, LG Chem’s partner, Rhythm Pharmaceuticals(hereinafter referred to as 'Rhythm'), announced the initiation of the first patient dosing in a Phase 2 clinical trial for LB54640.

Rhythm plans to recruit 28 patients aged 12 and older with hypothalamic obesity(HO), a condition characterized by impaired hypothalamic function leading to difficulties in appetite control. The primary efficacy endpoint will assess changes in body mass index(BMI) after 14 weeks of treatment, with an extension study to evaluate long-term safety over 52 weeks of continued treatment.

LB54640 is an MC4R(Melanocortin-4 Receptor) agonist developed in-house by LG Chem, which was globally licensed to Rhythm in January. The drug has been recognized for its high potential, recording the highest upfront payment in the domestic pharmaceutical industry for technology exports in the first half of the year, amounting to $100 million.

In a corporate presentation to investors held in May, Rhythm identified the acceleration of LB54640 development as one of the three key initiatives to enhance company value, signaling a strong commitment to active investment. Rhythm is focusing on expanding the indications and global reach of its already commercialized MC4R agonist, IMCIVREE, which requires daily injections. Simultaneously, the company is accelerating the development of MC4R agonists such as LB54640 and RM-718, which offer improved dosing convenience.

David Meeker, CEO and President of Rhythm Pharmaceuticals, stated, "Based on preclinical and Phase 1 clinical data, we have confirmed the potential of LB54640 as an effective MC4R agonist without adverse effects such as skin pigmentation." He added, "We are committed to providing a broad portfolio of treatment options, enabling patients worldwide who suffer from severe obesity to select the most appropriate therapy for their needs."